Kymera outlines plans for KT-621 Phase IIb data in 2027 as cash runway extends into 2029
Source: SeekingAlpha
2026-02-26 15:09:28 ET
More on Kymera Therapeutics
- Kymera Therapeutics, Inc. (KYMR) Q4 2025 Earnings Call Transcript
- Kymera Therapeutics: The More This Biotech Spends, The Higher Its Valuation Rises
- Kymera Therapeutics, Inc. (KYMR) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Kymera Therapeutics Q4 2025 Earnings Preview
- Kymera Therapeutics prices $602M public offering at $86.00 a share
Read the full article on Seeking Alpha
For further details see:
Kymera outlines plans for KT-621 Phase IIb data in 2027 as cash runway extends into 2029
Kymera Therapeutics Inc.
NASDAQ: KYMR
KYMR Trading
-0.26% G/L:
$77.675 Last:
154,819 Volume:
$78.18 Open:
KYMR Latest News
March 10, 2026 07:00:00 am
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting
February 26, 2026 07:00:00 am
Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
KYMR Stock Data
$6,259,529,627
60,213,376
0.01%
74
N/A
Biotechnology & Life Sciences
Healthcare
US
Watertown
